The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASTRO 2022 | The impact of KRAS mutation and PD-1 status on outcomes of SBRT for NSCLC
Kevin Stephans, MD, Cleveland Clinic, Cleveland, OH, discusses the impact of KRAS mutation and PD-1 status on outcomes of stereotactic body radiation therapy (SBRT) in non-small cell lung cancer (NSCLC). This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
